Randomized Phase I/II of Rapamycin Analog, RAD001, in Advanced Hepatocellular Carcinoma - With a Pharmacokinetic Study of RAD001

Trial Profile

Randomized Phase I/II of Rapamycin Analog, RAD001, in Advanced Hepatocellular Carcinoma - With a Pharmacokinetic Study of RAD001

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 30 Jun 2010 Reults reported at the 12th World Congress on Gastrointestinal Cancer 2010.
    • 07 Jul 2009 Planned end date changed from 1 Dec 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
    • 31 May 2009 Interim results presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top